The Bacterial Vaginosis drugs in development market research report provides comprehensive information on the therapeutics under development for Bacterial Vaginosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Bacterial Vaginosis. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Bacterial Vaginosis and features dormant and discontinued products.
GlobalData tracks 27 drugs in development for Bacterial Vaginosis by 26 companies/universities/institutes. The top development phase for Bacterial Vaginosis is preclinical with ten drugs in that stage. The Bacterial Vaginosis pipeline has 26 drugs in development by companies and one by universities/ institutes. Some of the companies in the Bacterial Vaginosis pipeline products market are: Dare Bioscience, Shanghai Sine Pharmaceutical Laboratories and Osel.
The key targets in the Bacterial Vaginosis pipeline products market include Bacterial Cell Wall, Bacterial Cell Membrane, and 23S Ribosomal RNA.
The key mechanisms of action in the Bacterial Vaginosis pipeline product include Bacterial Cell Wall Disruptor with two drugs in Phase I. The Bacterial Vaginosis pipeline products include five routes of administration with the top ROA being Vaginal and five key molecule types in the Bacterial Vaginosis pipeline products market including Biologic, and Small Molecule.
Bacterial Vaginosis overview
Bacterial vaginosis (BV), also known as vaginal bacteriosis, is a type of vaginal inflammation caused by the overgrowth of bacteria present in the vagina. Symptoms include vaginal itching, burning during urination, and watery and thin vaginal discharge. Treatment includes antibiotics.
For a complete picture of Bacterial Vaginosis’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
